South Korea Carglumic Acid Market Insight
Published: 19 June 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The South Korea carglumic acid market is expected to witness robust growth at a CAGR of 5.83% owing to rising primary application, dosage forms, market drivers.
South Korea Carglumic Acid Market Insights Forecasts to 2035
- The South Korea Carglumic Acid Market Size Was Estimated USD 8.4 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.83% from 2025 to 2035
- The South Korea Carglumic Acid Market Size is Expected to rise around USD 14.8 Million by 2035
Notable Insights for the South Korea Carglumic Acid Market
- Based on the Segmentation by Product Type, it can be observed that the Orally Dispersible Tablets segment is taking lead in South Korea Carglumic Acid Market in 2025, holding almost 54% share.
- The application of the Segmentation by Application shows that in 2025, the N-Acetylglutamate Synthase (NAGS) Deficiency Treatment segment accounted for approximately 61% of the South Korean Carglumic Acid market share.
- The revenue generated in the global Recordati Rare Diseases Business for the year ended 2025 is estimated at $1.2 billion due to the increasing need for orphan metabolic therapies, precision clinical products, and specialized therapeutic options.
- More investment in artificial intelligence-based screening as well as developing target drugs and diagnostics for rare diseases will enhance the growth trends of these markets, as seen by recent improvements in advanced therapeutic components to provide 42% better dosage accuracy and lessen degradation throughout the manufacturing process.
Download the eBook (ToC)
What Makes Decisions Advisors Research Unique?
- Intelligent Market Research Based on AI for Semiconductors & Rare Diseases
Decisions Advisors offers intelligent market research which includes advanced analysis of biochemical therapeutics, rare metabolic pharmaceuticals, AI-driven diagnostic screening solutions, and localized health policy tracks. Our research identifies potential areas of business development, technology adoption rates, competitive position analysis, and important strategic changes in South Korea Carglumic Acid Market.
- Highly Effective Research Approaches with Accurate Forecast Analysis
The research process uses advanced methodologies such as primary research interview approaches, industry research, tracking the clinical drug supply chain, and data triangulation to deliver accurate market sizing, CAGR forecasting, investment analysis, and technology forecasting. The study examines the demand for specialized therapeutic solutions in regional medical universities, clinical research centers, rare disease registries, and designated specialized hospitals in South Korea.
- Highly Competitive Environment Analysis
In-depth analysis of key orphan drug suppliers, active pharmaceutical ingredient innovations, AI-enabled health tracking systems, product launch activities, and strategic collaborations is included in the report. The report also covers rare disease regulations, technology research and development analysis, smart therapeutic infrastructure, and new opportunities available in the South Korea Carglumic Acid Market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea Carglumic Acid Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Carglumic Acid Market
-
- Recordati Rare Diseases Korea
- Civica Rx Division
- Eton Pharmaceuticals (Korea Regional Sales)
- Anpharm Co., Ltd.
- AstraZeneca Korea (Rare Disease Business Unit)
- Sanofi Genzyme Korea
- Takeda Pharmaceuticals Korea
- GC Biopharma (Green Cross Corporation)
- Hanmi Pharmaceutical Co., Ltd.
- Daewoong Pharmaceutical Co., Ltd.
Recent Developments:
-
- In September 2025, Recordati Rare Diseases launched new dispersible tablets with enhanced dissolving stability systems aimed at enabling physician-patient metabolic monitoring and improving patient management for hyperammonemia.
-
- In April 2025, Eton Pharmaceuticals released new advanced carglumic acid clinical formulations intended for local metabolic hospitals, pediatric care units, and clinical tracks for distributing rare disease therapies.
Market Segmentation:
South Korea Carglumic Acid Market, By Product Type
-
- Orally Dispersible Tablets
- Soluble Powder Formulations
- High-Purity Active Ingredients
- Film-Coated Targeted Tablets
- Modular Unit-Dose Packages
South Korea Carglumic Acid Market, By Technology
-
- AI-Based Target Drug Screening
- Low-Temperature Crystal Fabrication
- High-Stability Additive Formulations
- Precision Chemical Vapor Synthesis
- Real-Time Pharmacokinetic Assay Systems
South Korea Carglumic Acid Market, By Application
-
- NAGS Deficiency Therapeutics
- Organic Acidemia Intervention
- Isovaleric Acidemia Management
- Methylmalonic Acidemia Tracking
- Acute Hyperammonemia Emergency Care
Expert Views:
Factors impacting the South Korean market for carglumic acid include an increased use of intelligent solutions for clinical practice, continued development of orphan drugs that target specific diseases, and increasing need for specialized therapeutics. The synergy created by the introduction of molecular screening systems powered by AI; optimised additive formulations; and more effective testing methods will enable significant gains in the effectiveness of procedure performance and greater demand at metabolic disorders diagnostic laboratories, regional healthcare providers, through the therapeutic channels providing treatment of rare diseases.
Author: Govind and Krishna By Decisions Advisors and Consulting